Table 1 Course of response measures during 12 weeks of adalimumab treatment.

Time	Swollen joints* (n)	Tender joints* (n)	Patient's global assessment of pain* (VAS)	IL6 serum levels* (pg/ml)
Baseline	8.8 (0.7) {9.1 (0.6)}	10.5 (0.8) {9.5 (0.5)}	54.8 (4.5) {54.8 (3.7)}	21.6 (7.4) {33.9 (12.2)}
Week 2	7.3 (0.9) {7.0 (0.7)}	9.6 (0.7) {8.1 (0.5)}	40.8 (3.5) {40.7 (5.3)}	4.1 (1.8) {7.0 (1.8)}
Week 6	4.3 (0.9) {4.3 (0.6)}	7.5 (0.80) {6.5 (0.7)}	32.3 (3.8) {38.5 (3.8)}	8.7 (5.3) {5.5 (2.1)}
Week 12	2.8 (0.5) {3.4 (0.6)}	6.1 (0.5) {5.4 (0.7)}	23.3 (3.7) {25.2 (4.7)}	2.9 (0.9) {13.8 (8.5)}

Data of patients with prednisolone treatment are given in {brackets}. Data are given as means (SEM).

*p<0.003 indicating a decrease as assessed by the Friedman test.